These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 24225343)

  • 1. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
    von Bibra M; Rosenkranz B; Pretorius E; Rabie H; Edson C; Lenker U; Cotton M; Klinker H
    Paediatr Int Child Health; 2014 May; 34(2):138-41. PubMed ID: 24225343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir serum concentrations of critically ill infants: a pharmacokinetic investigation in South Africa.
    Schultheiß M; Kling S; Lenker U; von Bibra M; Rosenkranz B; Klinker H
    Med Microbiol Immunol; 2018 Nov; 207(5-6):339-343. PubMed ID: 29974233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.
    Viljoen M; Gous H; Kruger HS; Riddick A; Meyers TM; Rheeders M
    AIDS Res Hum Retroviruses; 2010 Jun; 26(6):613-9. PubMed ID: 20507205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
    Engelbrecht AE; Wiesner L; Norman J; Rabie H; Decloedt EH
    J Trop Pediatr; 2020 Aug; 66(4):385-394. PubMed ID: 31754710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
    Gandhi M; Mwesigwa J; Aweeka F; Plenty A; Charlebois E; Ruel TD; Huang Y; Clark T; Ades V; Natureeba P; Luwedde FA; Achan J; Kamya MR; Havlir DV; Cohan D;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):578-84. PubMed ID: 24135775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
    Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
    J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.
    Oumar AA; Bagayoko-Maiga K; Bahachimi A; Maiga M; Cere MC; Diarra Z; Chatelut E; Sylla M; Murphy RL; Dao S; Gandia P
    J Pharmacol Exp Ther; 2018 Sep; 366(3):479-484. PubMed ID: 29986950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
    von Hentig N; Koenigs C; Elanjikal S; Linde R; Dunsch D; Kreuz W; Funk MB
    Eur J Med Res; 2006 Sep; 11(9):377-80. PubMed ID: 17101460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
    ter Heine R; Scherpbier HJ; Crommentuyn KM; Bekker V; Beijnen JH; Kuijpers TW; Huitema AD
    Antivir Ther; 2008; 13(6):779-87. PubMed ID: 18839779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.
    Goicoechea M; Vidal A; Capparelli E; Rigby A; Kemper C; Diamond C; Witt MD; Haubrich R;
    Antivir Ther; 2007; 12(1):55-62. PubMed ID: 17503748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
    Fayet-Mello A; Buclin T; Guignard N; Cruchon S; Cavassini M; Grawe C; Gremlich E; Popp KA; Schmid F; Eap CB; Telenti A; Biollaz J; Decosterd LA; Martinez de Tejada B; ;
    Antivir Ther; 2013; 18(2):171-82. PubMed ID: 22914504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.
    Prasitsuebsai W; Kerr SJ; Truong KH; Ananworanich J; Do VC; Nguyen LV; Kurniati N; Kosalaraksa P; Sudjaritruk T; Chokephaibulkit K; Thammajaruk N; Singtoroj T; Teeraananchai S; Horng H; Bacchetti P; Gandhi M; Sohn AH
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1009-14. PubMed ID: 26200586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
    Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR
    J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.
    Pressiat C; Amorissani-Folquet M; Yonaba C; Treluyer JM; Dahourou DL; Eboua F; Blanche S; Mea-Assande V; Bouazza N; Foissac F; Malateste K; Ouedraogo S; Lui G; Leroy V; Hirt D
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.